In this video, Arshad M. Khanani, MD, MA, FASRS, discusses the results of the GALE open-label extension study of pegcetacoplan in patients with geographic atrophy presented at the American Academy of Ophthalmology meeting.
Patients experienced a reduction in geographic atrophy growth following 36 months of treatment with pegcetacoplan, which was approved by the FDA in February, according to Khanani, director of clinical research at Sierra Eye Associates.“We continue to see an increase in benefit in patients who were treated with monthly or every other month pegcetacoplan,” he said.